Cargando…

Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis

BACKGROUND: Immune checkpoint inhibitors may be associated with multiple immune-related toxicities. Cardiovascular adverse effects are underreported in clinical trials. METHODS: We conducted a systematic review and meta-analysis to evaluate cardiovascular adverse effects incidence among patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xavier, Camila Bragança, Lopes, Carlos Diego Holanda, Harada, Guilherme, Peres, Eduardo Dante Bariani, Katz, Artur, Jardim, Denis Leonardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898968/ https://www.ncbi.nlm.nih.gov/pubmed/35248919 http://dx.doi.org/10.1016/j.tranon.2022.101383

Ejemplares similares

Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology
por: Jardim, Denis L., et al.
Publicado: (2018)

Campylobacteriosis following immunosuppression for immune checkpoint inhibitor-related toxicity
por: Lee, Karla A, et al.
Publicado: (2020)

A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities
por: Naidoo, Jarushka, et al.
Publicado: (2020)

Key Characteristics of Cardiovascular Toxicants
por: Lind, Lars, et al.
Publicado: (2021)

Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors
por: Xavier, Camila B., et al.
Publicado: (2022)

Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions?
por: Metro, Giulio, et al.
Publicado: (2020)

Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors
por: Pirozzi, Flora, et al.
Publicado: (2021)

Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians
por: Raschi, Emanuel, et al.
Publicado: (2023)

Risk Factors for Immune Checkpoint Inhibitor–Mediated Cardiovascular Toxicities
por: Yousif, Laura I., et al.
Publicado: (2023)

The gut microbiota and immune checkpoint inhibitors
por: Humphries, Audrey, et al.
Publicado: (2018)

Immune Checkpoint Glycoproteins Have Polymorphism: Are Monoclonal Antibodies Too Specific?
por: Jalalizadeh, Mehrsa, et al.
Publicado: (2023)

Immune checkpoint inhibitor-related acral vasculitis
por: Comont, Thibault, et al.
Publicado: (2018)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

Gamma glutamyl transferase: A novel cardiovascular outfit for an old liver test
por: Lonardo, Amedeo, et al.
Publicado: (2016)

The Diagnosis and Management of Immune Checkpoint Inhibitor Cardiovascular Toxicity: Myocarditis and Beyond
por: Gilon, Dan, et al.
Publicado: (2022)

Antibiotic therapy and outcome from immune-checkpoint inhibitors
por: Pinato, David J., et al.
Publicado: (2019)

COVID-19 and immune checkpoint inhibitors: initial considerations
por: Sullivan, Ryan J, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab
por: Bukamur, Hazim, et al.
Publicado: (2020)

Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors?
por: Dillman, Robert O.
Publicado: (2016)

Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma
por: Akhuba, Liia, et al.
Publicado: (2023)

Gene expression profiles (GEPs) of immuno-oncologic pathways as predictors of response to checkpoint inhibitors in advanced NSCLC
por: De Marchi, Pedro, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke
por: Belluomini, Lorenzo, et al.
Publicado: (2019)

Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors
por: Bersanelli, Melissa
Publicado: (2020)

How Compatible Are Immune Checkpoint Inhibitors and Thermal Ablation for Liver Metastases?
por: Minami, Yasunori, et al.
Publicado: (2022)

Combining STAT3-Targeting Agents with Immune Checkpoint Inhibitors in NSCLC
por: Papavassiliou, Kostas A., et al.
Publicado: (2023)

Revisiting checkpoint inhibitors for myeloma: maintenance after stem cell transplant
por: Meermeier, Erin W., et al.
Publicado: (2023)

Immune checkpoint inhibitors: here to stay
por: Carvalho, Filomena Marino, et al.
Publicado: (2023)

Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
por: Ascierto, Paolo A., et al.
Publicado: (2017)

Misregulated Posttranscriptional Checkpoints: Inflammation and Tumorigenesis
por: Brewer, Gary
Publicado: (2001)

Update on checkpoint blockade therapy for lymphoma
por: Kline, Justin, et al.
Publicado: (2015)

Immune Checkpoint Inhibitor–Related Cardiovascular Toxicity in Lung Cancer: Is Routine Screening Indicated?
por: Sun, Lova, et al.
Publicado: (2019)

A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer
por: Antonarakis, Emmanuel S.
Publicado: (2019)

Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer
por: Yu, Peter Paul, et al.
Publicado: (2019)

Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment
por: Rossi, Ernesto, et al.
Publicado: (2020)

Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?
por: Haratani, Koji, et al.
Publicado: (2020)

Immune checkpoint inhibitor-related hypogonadism and infertility: a neglected issue in immuno-oncology
por: Özdemir, Berna C
Publicado: (2021)

Checkpoint inhibitors are a basic science‐based, transformative new treatment for lung cancer
por: Miller, Alistair R.
Publicado: (2022)

Some assembly required: Redefining the mitotic checkpoint
por: Meadows, John C., et al.
Publicado: (2017)

The Puzzle of Predicting Response to Immune Checkpoint Blockade
por: Onyshchenko, Mykola
Publicado: (2018)

Management of hepatitis B in the era of checkpoint inhibition
por: Dutcher, Janice
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1au70pni8j2gsijagd1ohej3jg